---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-193376"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2022-07-14T23:59:59+00:00"
generated_at: "2026-06-24T15:27:17.757205+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD terminates Merger Agreement; debt maturity extended to July 24; evaluating Chapter 11

## Summary
- Tender offer at $10/share expired July 12 without acquiring required majority; Merger Agreement terminated July 13.
- Debt maturity under Financing Agreement extended to July 24, 2022; Company paid $1.2M paid-in-kind amendment fee.
- Board evaluating all options including potential refinancing and Chapter 11 filing; normal operations continue during evaluation.

## SEC filing metadata
- accession: 0001193125-22-193376
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2022-07-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000119312522193376/0001193125-22-193376-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000119312522193376/d338419d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-193376
- JSON: https://secwatch.observer/filing/0001193125-22-193376.json
- Plain text: https://secwatch.observer/filing/0001193125-22-193376.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.